Pioneering Precision Endocrine Peptides (PEPs™) to transform the treatment of endocrine and metabolic disorders.
Joined April 2019
- Tweets 84
- Following 176
- Followers 90
- Likes 0
80 Photos and videos
Jun 12
MBX Biosciences announced full 12-week Avail™ Phase 2 results and new one-year OLE data supporting its once-weekly parathyroid hormone replacement therapy candidate in adults with chronic hypoparathyroidism. Join the webcast: investors.mbxbio.com/news-ev….
1
13
Jun 1
June 1 marks #WorldHypoparaDay, spotlighting #hypoparathyroidism (HP) and the 100K people in the U.S. living with this rare disorder. At MBX, we’re proud to partner with @HypoPARAassoc and leverage our Precision Endocrine Peptide™ platform to continue advancing progress for HP.
1
15
Jun 1
MBX to host investor webcast June 12 (8am ET) ahead of #ENDO2026 in Chicago, highlighting Phase 2 data in hypoparathyroidism.
• 1-year OLE data (June 12)
• Full 12-week results (June 13)
Join: investors.mbxbio.com/news-ev…
2
19
May 26
MBX is attending the @Jefferies 2026 Global Healthcare Conference in NYC on June 3. CEO Kent Hawryluk & CMO Sam Azoulay, M.D. will discuss progress advancing precision peptide therapies for endocrine and metabolic disorders. investors.mbxbio.com/news-ev…
1
30
May 20
On #ClinicalTrialsDay, we thank the researchers and patients who move clinical research forward. Their dedication and trust enable progress and help bring new therapies closer to those who need them most. Learn more about MBX’s clinical programs: mbxbio.com/our-pipeline
1
12
May 11
MBX to present Obesity Portfolio updates at Obesity Day (10:30am ET) including initial Ph1 data for MBX 4291 (GLP‑1/GIP co‑agonist). Register here: investors.mbxbio.com/news-ev…
1
37
May 7
MBX announces Q1 2026 earnings and the appointment of global biopharma commercial leader, Mark Soued, MBA as Chief Commercial Officer, as the Company advances its proprietary Precision Endocrine Peptides (PEPs)™ pipeline. investors.mbxbio.com/news-ev…
1
33
Apr 24
This #WorldHormoneDay, MBX joins @ESEndocrinology to spotlight the impact of hormone imbalances – from obesity to 400 rare endocrine diseases including hypoparathyroidism. We’re advancing Precision Endocrine Peptides™ to address unmet needs. Learn more: mbxbio.com
1
3
65
Apr 23
MBX will host an in-person and virtual Obesity Day on Monday, May 11, 2026 at 10:30 a.m. ET to provide an update on its expanding obesity portfolio. Register here: lifescievents.com/event/hlg0…
1
30
Apr 20
We’re #Hiring! At MBX, we’re looking for researchers and clinical & regulatory professionals to join our mission to improve care for rare endocrine and metabolic disorders. Explore our open roles: mbxbio.com/careers
1
16
Apr 7
This #WorldHealthDay, MBX supports the @WHO's call to #StandWithScience. With a focus on science-led innovation through our proprietary PEP™ Platform, we aim to transform the treatment landscape for endocrine and metabolic diseases. Learn more: mbxbio.com
1
2
49
Mar 24
This Women’s History Month, we want to thank all the talented and driven women that embody our mission, values and operating principles in support of our goal to improve the lives of people living with endocrine and metabolic disorders.
1
33
Mar 12
Today, we shared our Q4 and full-year 2025 financial results. View our highlights and upcoming milestones in the press release: investors.mbxbio.com/news-re…
1
29
Mar 11
Our CEO, @KentHawryluk, has been appointed to the Biotechnology Innovation Organization @IAmBiotech Board of Directors, where his deep experience building organizations and commitment to patients will support BIO’s mission to expand innovation and improve medicine access.
1
2
35
Mar 10
Tomorrow, our CEO, @KentHawryluk, and CMO, Sam Azoulay, MD, are meeting with investors at the @Jefferies Biotech on the Beach Summit and participating in a fireside chat at the @Barclays 28th Annual Global Healthcare Conference. Access the webcast: investors.mbxbio.com/news-re…
1
45
Mar 10
#NEWS: Welcome Karen Basbaum, MBA, as Chief Business Officer at MBX! Ms. Basbaum’s two decades of leadership in biopharma will be crucial as we advance our pipeline and pursue strategic opportunities to maximize the impact of our therapies for patients. investors.mbxbio.com/news-re…
1
38
Mar 9
#NEWS: Today, we announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the @US_FDA to discuss the overall Phase 3 trial design for our once-weekly investigational therapy for the treatment of chronic #hypoparathyroidism. investors.mbxbio.com/news-re…
1
32
Mar 6
Chief Human Resource Officer, Michelle Graham, took a moment to reflect on #EmployeeAppreciationDay and to thank all the exceptional individuals who are making an impact every day through their dedication, collaboration, and commitment to patients here at MBX.
1
31
Mar 5
Next week, our CEO, @KentHawryluk, and CMO, Sam Azoulay, MD, are participating in a fireside chat at the @CitizensBank Life Sciences Conference and meeting with investors at the @UBS Biotech Summit. Access the presentation webcast here: investors.mbxbio.com/news-re…
1
48
Mar 4
We’re joining @WorldObesity to raise awareness of the unmet needs of people living with obesity. We’re advancing new potential therapeutic options, with a growing obesity pipeline built on our PEP platform, designed for once-monthly dosing and improved tolerability.
1
28